Jincheng Pharm(300233)2024-10-24 08:11Financial Performance - The company's revenue for Q3 2024 was ¥756,740,137.64, a decrease of 12.36% compared to the same period last year[1]. - Net profit attributable to shareholders was ¥20,462,246.05, down 33.50% year-on-year, while net profit excluding non-recurring items was ¥16,867,461.06, down 37.46%[1]. - The basic earnings per share for the period was ¥0.06, a decrease of 25.00% compared to the previous year[1]. - Total operating revenue for Q3 2024 was CNY 2,515,318,391.16, a decrease from CNY 2,568,752,667.57 in the same period last year, representing a decline of approximately 2%[10]. - The net profit for Q3 2024 was CNY 162,100,822.21, an increase of 10.0% compared to CNY 146,655,023.18 in Q3 2023[11]. - The operating profit for the quarter was CNY 195,266,352.27, an increase of 11.2% from CNY 175,516,338.76 in the same period last year[11]. - The company reported a total comprehensive income of CNY 162,100,822.21 for Q3 2024, compared to CNY 153,711,697.28 in Q3 2023, marking an increase of 5.5%[12]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,603,939,876.88, a decrease of 5.28% from the end of the previous year[1]. - Current liabilities totaled CNY 1,339,988,545.73, a decrease from CNY 1,600,325,890.83, showing a reduction of about 16.3%[10]. - Non-current assets decreased to CNY 3,392,226,128.67 from CNY 3,546,798,516.24, representing a decline of approximately 4.4%[9]. - The company's equity attributable to shareholders was CNY 3,699,709,849.54, slightly down from CNY 3,714,133,643.74, indicating a decrease of about 0.4%[10]. Cash Flow - The cash flow from operating activities showed a net outflow of ¥201,438,822.82, a decline of 56.30% year-on-year due to decreased sales and increased cash payments for raw materials[5]. - The net cash flow from operating activities for Q3 2024 was ¥201,438,822.82, a decrease of 56.3% compared to ¥460,921,031.06 in Q3 2023[14]. - The net cash flow from investing activities was -¥106,909,952.74, an improvement from -¥157,366,616.95 in the same period last year[14]. - The net cash flow from financing activities decreased by 66.72% to -155,619,037.29 RMB due to increased dividend and stock repurchase expenditures[6]. - The total cash and cash equivalents at the end of Q3 2024 stood at ¥847,173,261.89, down from ¥1,002,497,766.99 at the end of Q3 2023[14]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 27,841, with the largest shareholder, Zibo Jincheng Industrial Investment, holding 20.46% of shares[6]. - The top ten shareholders collectively held a significant portion of the company's equity, indicating concentrated ownership[6]. - The company reported a total of 12,170,274 shares under lock-up agreements, with various executives holding restricted shares[7]. Operational Highlights - The company experienced a 73.51% increase in special reserves, totaling ¥7,862,657.36, due to the accrual of special reserve balances[3]. - The company has not disclosed any new product developments or market expansion strategies in the current reporting period[6]. - There were no significant mergers or acquisitions reported during this quarter[6]. - The company is focused on maintaining its financial stability while managing shareholder expectations through dividends and stock buybacks[6]. Expenses and Investments - The company's financial expenses decreased by 83.23% to ¥1,558,021.75, attributed to reduced interest expenses and increased exchange gains[4]. - Research and development expenses amounted to CNY 122,556,886.36, slightly up from CNY 121,823,184.36, showing a marginal increase of 0.6%[11]. - The investment income showed a loss of CNY 1,524,342.93, compared to a loss of CNY 70,366.52 in the previous year, indicating a worsening in investment performance[11].